[1] |
LIU Saiyue, LYU Xiaoqin, ZHOU Yun.
Key points of investigation and report of suspected death of adverse drug reaction
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
|
[2] |
ZHAO Xuan, GUO Jing, CHEN Ning, MEI Long, ZHENG Tingting, ZHANG Lifang, ZHANG Wei.
Discuss the safety management of medical toxic drugs in medical institutions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 705-708.
|
[3] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[4] |
CHU Yanqi, JIANG Yongxian, SHEN Jianghua, XING Xiaoxuan, ZHANG Qingxia, YAN Suying.
Analgesia-related risks after thoracoscopic surgery in elderly patients
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1023-1026.
|
[5] |
LUO Yichong, CAI Liping, PU Yanfang, ZHAO Jinhua.
Routes of Administration Described in Specifications of 236 Types of Intravenous Injections
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 872-875.
|
[6] |
GENG Hongjiao, WANG Lianxin, XIE Yanming.
Pharmacovigilance of Chinese Medicine in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 552-555.
|
[7] |
SA Rina, ZHANG Bing, LIN Zhijian, WANG Xiaofang, ZHANG Xiaomeng.
Pharmacovigilance of Traditional Chinese Medicine in Pharmaceutical Care in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 422-426.
|
[8] |
JU Shan, LIU Yinghui, WANG Yawen, TENG Yingying, JIANG Yan, DENG Gang, SUN Lei.
Clinical Evaluation of Medical Devices Seen from International Coordination Documents
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1062-1065.
|
[9] |
FENG Yanan, LIU Xinxin, LI Yonghui, WANG Fang, GUO Ruifeng.
Challenges to Pharmacovigilance by Medical Institutions under the New Drug Administration Law
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 572-573.
|
[10] |
HUANG Yuan, WANG Chenggang, WU Shifu, WANG Ling, TIAN Yuejie, WU Chen, WANG Xiaojun.
Drug Abuse Monitoring Models in Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 607-612.
|
[11] |
WANG Jiayu, YU Dandan, LI Ming, WANG Ling, LIU Pengcheng, SUN Jun.
Current Abuse/Use of Compound Tramadol in Drug Abusers
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 98-105.
|
[12] |
LIU Huan, ZHANG Zhongyi, YANG Yue.
Safety Report Management in New Drug Clinical Trials
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(2): 88-93.
|
[13] |
HONG Wei, WANG Feng.
Current Construction of Monitoring and Evaluation System of Adverse Drug Reactions in Anhui Province
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 722-726.
|
[14] |
WANG Dan, LI Xinling, DONG Duo, XIONG Weiyi, LIU Cuili, ZHU Lan, GENG Fengying, LIAO Jianbo, YANG Yueming, LAN Shan, LV Xiaoqin, WANG Tongchun, ZHAO Xia, WANG Wen.
Investigation of Pharmaceutical Manufacturers’ Ability of Direct Reporting of Drug Adverse Reactions
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 654-661.
|
[15] |
SHI Bing-juan.
Thinking on Improving and Guaranteeing the Quality of Traditional Chinese Medicine Preparations in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 276-279.
|